Genflow Biosciences PLC (LON: GENF) has reported encouraging preliminary interim results from its SLAB clinical trial assessing its SIRT6 gene therapy in aged dogs.

Genflow Biosciences Plc (LON: GENF) has appointed Gad Berdugo as Independent Non-Executive Chairman, a move intended to support the group’s next phase of corporate development and R&D expansion.

Genflow Biosciences PLC (LON: GENF) said it made solid operational progress during 2025, advancing multiple programmes across aging, metabolic disease and gene therapy, while laying the groundwork for a more

Genflow Completes Dosing Phase of Canine Gene Therapy Trial No Adverse Events Reported During Administration

Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference

Update on Animal Health Program

Genflow Biosciences Raises £440,000 Through Alternative Share Placement.

Genflow Biosciences PLC  (LON: GENF) has submitted a formal request for examination of its patent application in China relating to proprietary SIRT6 variants designed for the treatment of Non-Alcoholic Steatohepatitis

Genflow Biosciences PLC (LSE: GENF, OTCQB: GENFF) has announced progress across its two core research programmes, bringing it closer to initiating human trials for its gene therapies targeting age-related diseases.

Genflow Biosciences Advances SIRT6 Variant Patent Application Following Positive Search Report from European Patent Office